Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand’s long-acting GLP-2 analog glepaglutide

by on November 14, 2017

Press Release- No. 11/2017 Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand’s long-acting GLP-2 analog glepaglutide All 75 subjects dosed with glepaglutide in the clinical trial The trial was initiated based on positive Phase 2 results reported in June 2017 in patients with short bowel syndrome Results from the trial are expected in Q1 2018 Copenhagen, Denmark, November 14, 2017 – Zealand Pharma announces that all subjects have been enrolled and dosed in a clinical trial with glepaglutide under an investigational new drug application (IND) for the treatment of short bowel syndrome (SBS). Following positive results from a…
WN.com – Science News

Comments on this entry are closed.

Previous post:

Next post: